International companies are increasingly inking licensing deals with China biotechs as concerns regarding drug pricing and ...

Even with the HIV prevention waters now dominated by Gilead Science’s Yeztugo (lenacapavir), Merck & Co. is not afraid to swim deeper in. | Even with the HIV prevention waters now dominated by Gilead ...

BD has found a new home for its biosciences and diagnostics divisions at the lab equipment maker Waters Corporation, through ...

Essa Pharma, which had been resisting pressure from activist investors to wind down operations, has now agreed a deal to ...

Choosing the right specialty pharmacy partner is critical. Especially when you’re treating rare, chronic and complex conditions. You need a partner who delivers more than just logistics management, ...

Takeda is on track to submit its much-hyped narcolepsy drug to regulators this fiscal year after the orexin receptor 2 (OX2R)-selective agonist ...

AstraZeneca’s $1.3 billion bet on CinCor Pharma and its mid-phase hypertension drug baxdrostat seems to have paid off based ...

After prematurely ending two phase 3 depression trials last year, Relmada Therapeutics has formally given up on the asset ...

Quest Diagnostics has signed up to offer a blood test that can help diagnose Alzheimer’s disease, following its FDA clearance earlier this year. | The Lumipulse G blood test measures the ratio between ...

Karyopharm Therapeutics is laying off 20% of staffers as efforts to secure a strategic alternative have turned up short. | ...

The FDA has rejected Capricor Therapeutics’ filing for approval of a Duchenne muscular dystrophy (DMD) cell therapy, raising ...

Layoffs in biopharma show no signs of slowing, with workforce reductions holding steady across the first two quarters of 2025. | Biopharma layoffs have held steady through mid-2025, and in this ...